{"id":2936,"date":"2022-03-02T12:43:14","date_gmt":"2022-03-02T09:43:14","guid":{"rendered":"https:\/\/bpklinik.com\/?page_id=2936"},"modified":"2023-03-12T19:51:13","modified_gmt":"2023-03-12T19:51:13","slug":"ueber-uns","status":"publish","type":"page","link":"https:\/\/bpklinik.com\/de\/ueber-uns\/","title":{"rendered":"\u00dcber Uns"},"content":{"rendered":"\n

Die BP-Klinik ist ein Ort, der nach dem Motto „personalisierte Gesundheit, personalisierte Onkologie“ mit \u00c4rzten und Spezialisten aus den verschiedensten Fachrichtungen arbeitet, was in dieser Form im Land beispiellos ist. Anders als das konventionelle Gesundheitssystem, welches darauf ausgerichtet ist, Erkrankungen zu behandeln, hilft es den Menschen, gar nicht erst krank zu werden.<\/p>\n\n\n\n

Prof. Dr. Berrin Pehlivan, Strahlenonkologin, schloss ihr Studium an der Hacettepe Universit\u00e4t im Jahr 2000 ab und setzte ihre Studien in Frankreich und in der Schweiz f\u00fcr weitere 4,5 Jahre fort, nachdem sie ihre Spezialisierung an derselben Universit\u00e4t erhalten hatte. Nach ihrer R\u00fcckkehr in ihre Heimat schloss sie ihren MBA ab und ist derzeit Fakult\u00e4tsmitglied an der Bah\u00e7e\u015fehir-Universit\u00e4t. Sie spricht Englisch und Franz\u00f6sisch, hat das Buch \u201c50 Fragen zu Krebs\u201d geschrieben und schreibt eine Kolumne in der Milliyet Zeitung unter dem Titel \u201cWissenschaftliches Tagebuch\u201d.<\/p>\n\n\n\n

Die Arbeit in dieser Klinik ist wie ein Dankesch\u00f6n an die Leser von Milliyet Cadde, sagt Prof. Dr. Berrin Pehlivan: „Ich habe auf allen Kan\u00e4len, auf denen ich seit langem zitiert werde, zu meinem Buch \u201c50 Fragen zu Krebs\u201d – und in meinen Artikeln immer wieder betont: \u201cBitte achten Sie auf Ihre Gesundheit, denn auch f\u00fcr Krebs und andere chronische Krankheiten gibt es eine Zeit f\u00fcr Diagnose und Behandlung\u201d.<\/p>\n\n\n\n

Es gibt ein Vorher, eine Diagnose, eine Behandlung und nat\u00fcrlich ein Nachher. Holen Sie sich die Meinung meiner Kollegen aus allen relevanten Disziplinen ein, \u00fcberwinden Sie Krankheit in einem Team, opfern Sie nicht Ihre Lebensqualit\u00e4t oder verfallen nach einer Behandlung in Panik. Man hat mich nach einem Ort der Heilung gefragt und was man unternehmen kann. Letztlich habe ich das getan, was ich als notwendig erachtet habe  – und konsequenterweise diese Klinik er\u00f6ffnet.<\/p>\n\n\n\n

Gesund zu bleiben im neuen Jahrhundert ist letztlich etwas Ma\u00dfgeschneidertes!
<\/strong>W\u00e4hrend der Wunsch, gesund zu leben, vor der Pandemie oft wie eine Modeerscheinung vor sich hergetragen wurde, wurde er durch die Erfahrungen der Pandemie zur Notwendigkeit. Wir wissen heute, dass nur sehr wenige Krankheiten erblich bedingt sind und dass die Ursache vieler Krankheiten, insbesondere von Krebs, durch unser Verhalten beeinflusst wird. Doch wissen wir, dass wir unsere Gesundheit auf den richtigen Weg bringen k\u00f6nnen, wenn wir uns nach unseren individuellen Eigenschaften richten und nicht irgendwelchen Halbwahrheiten folgen. Wir m\u00fcssen unseren Lebensstil, unser Verhalten, das, was wir essen, was wir trinken und alles, was wir erleben, nicht nach diesem oder jenem, sondern nach unserer k\u00f6rperlichen und genetischen Grundlagen ausrichten. Es gibt nicht eine einzige Medizin, eine einzige Behandlung oder nur einen einzigen Ansatz, der uns alle in gleicher Weise heilen kann!<\/p>\n\n\n\n

DIENSTE
<\/strong>F\u00fcr wen welche Behandlung geeignet ist, bestimmen wir individuell durch Gentests. Wir verf\u00fcgen \u00fcber ein Gremium, welches die Ergebnisse der Gentests auswertet.<\/p>\n\n\n\n

Wir haben die M\u00f6glichkeit, modernste Technologie in der Strahlentherapie anzuwenden; wir wenden erfolgreich IMRT, Arc und radiochirurgische Behandlungen an. Dar\u00fcber hinaus k\u00f6nnen wir alle Arten von unterst\u00fctzenden Therapien anwenden, einschlie\u00dflich Hyperthermie, Ozonbehandlung, hochdosiertes Vitamin C, welches die Wirksamkeit von Strahlentherapie, Immuntherapie usw. zus\u00e4tzlich erh\u00f6ht.<\/p>\n\n\n\n

Unser Team befasst sich nicht nur isoliert mit der Krankheit, sondern auch mit den Sorgen, der Ern\u00e4hrung, den Gewohnheiten und der psychischen Verfassung unserer Patienten. Unser Team besteht aus \u00c4rzten und Gesundheitsexperten aus den Bereichen Di\u00e4t und Ern\u00e4hrung, Psychologie, Physiotherapie und Onkologie.<\/p>\n\n\n\n

Es geht nicht nur darum, eine akute Krebserkrankung zu heilen, sondern auch darum, zu erkennen, ob man etwas falsch gemacht hat oder etwas vers\u00e4umt hat, was zur Erkrankung f\u00fchrte – denn nur ein kleiner Prozentsatz aller Krebserkrankungen ist erblich bedingt.
Nach einer bestm\u00f6glichen Behandlung unterst\u00fctzen wir Sie darin, diese m\u00f6glichen Fehler zu finden und Ihr Leben so zu gestalten, dass das Risiko eines erneuten Auftretens minimiert wird. Dies ist nat\u00fcrlich jeweils eine sehr individuelle Arbeit. Innerhalb eines interaktiven Prozesses, in den Sie eingebunden sind, zeigen wir Ihnen einen Weg auf, der ganz individuell auf Sie und Ihre Bed\u00fcrfnisse zugeschnitten ist. Mit stereotypen Standardempfehlungen, wie sie jedem empfohlen werden, werden Sie bei uns nicht abgespeist. Auf der Grundlage von Gentests zeigen wir Ihnen die – f\u00fcr Sie – optimale Lebensweise und Ern\u00e4hrung auf.<\/p>\n\n\n\n

In unserer Klinik f\u00fchren wir Krebsvorsorgeuntersuchungen, auf Gentests basierende Rezepte f\u00fcr ein gesundes Leben, Ozontherapie und antioxidative Behandlungen durch.<\/p>\n\n\n\n

Zu unserem Team geh\u00f6ren insbesondere ein Psychologe, ein Physiotherapeut, ein Psychiater, ein Di\u00e4tassistent sowie ein Spezialist f\u00fcr Endokrinologie und Stoffwechselerkrankungen. F\u00fcr unsere Krebspatienten bieten der beratende medizinische Onkologe und die Chirurgen der jeweiligen Abteilungen Unterst\u00fctzung an.<\/p>\n\n\n\n

Die BP-Klinik bietet zahlreiche intraven\u00f6se Behandlungsm\u00f6glichkeiten mit unterschiedlichen Heilungsans\u00e4tzen. Manchmal braucht nur ein einziger Wirkstoff eingesetzt werden, um die gew\u00fcnschte Wirkung zu erzielen, manchmal sind  Kombinationsbehandlungen sinnvoll. Welchen Ansatz wir letztlich w\u00e4hlen, h\u00e4ngt von den Beschwerden, den gesundheitlichen Merkmalen und nat\u00fcrlich den Vorstellungen des Erkrankten ab.<\/p>\n\n\n\n

Einige Anwendungen, die wir implementiert haben:<\/strong><\/p>\n\n\n\n

– Anti-Aging
– Chronische M\u00fcdigkeit
– Immunit\u00e4t
– Gesundheit von Sportlern
– Hochdosiertes Vitamin C
– Antioxidantien-Therapien
– Gesundheit von Gehirn und Nervensystem
– Migr\u00e4ne
– Kater (nach Alkohol)
– Unterst\u00fctzende Therapien nach einer Krebsbehandlung<\/p>\n\n\n\n

50 Fragen zu Krebs<\/strong><\/h2>\n\n\n\n

Der Grund, warum ich dieses Buch geschrieben habe, besteht darin, Krebs nicht l\u00e4nger als eine  Gei\u00dfel aus einer mystischen Welt wahrzunehmen, die alle anderen menschlichen Krankheiten \u00fcberragt! Den Krebs in seiner ganzen Bl\u00f6\u00dfe, seiner Einfachheit und Hilflosigkeit vor dem menschlichen Willen und der Vernunft zu entbl\u00f6\u00dfen… Daf\u00fcr zu sorgen, dass Krebs als eine vermeidbare und besiegbare Krankheit erkannt wird… Der schwerwiegendste Grund, warum Einige – trotz allem – dieser Krankheit erliegen, sind falsche Gewohnheiten, die zu Krebs f\u00fchren, und die Hilflosigkeit, in die sich manche ergeben, sobald sie seinen Namen h\u00f6ren.<\/p>\n\n\n\n

Wenn wir den Willen haben, die richtigen Fragen zu stellen und die richtigen Antworten in unser Leben zu integrieren, dann  wird das Leben zu einem Fluss, der in uns selber flie\u00dft und nicht ein Strom, in dem wir mitgerissen werden.<\/p>\n\n\n\n

Wissenschaftliche Studien von Prof. Dr. Berrin Pehlivan<\/h2>\n\n\n\n

A. Artikel, die in internationalen Peer-Review-Zeitschriften ver\u00f6ffentlicht wurden:<\/strong><\/p>\n\n\n\n

    \n
  1. Yilmaz B, Somay E, Topkan E, Pehlivan B, Selek U. Pre-chemoradiotherapy low hemoglobin levels indicate increased osteoradionecrosis risk in locally advanced nasopharyngeal cancer patients. Eur Arch Otorhinolaryngol. 2023 Feb 7.<\/li>\n\n\n\n
  2. Somay E, Yilmaz B, Topkan E, Kucuk A, Pehlivan B<\/u><\/strong>, Selek U. Initial neutrophil-to-lymphocyte ratio predicts radiation-induced trismus in parotid gland cancer. Oral Dis.2022 Nov 8.<\/li>\n\n\n\n
  3. Somay E, Yilmaz B, Topkan E, Kucuk A, Haksoyler V, Pehlivan B<\/u><\/strong>, Selek U, Araz K. Hemoglobin-to-platelet ratio in predicting the incidence of trismus after concurrent chemoradiotherapy. Oral Dis 2022 Aug 29.<\/li>\n\n\n\n
  4. Topkan E, Selek U, Kucuk A, Pehlivan <\/u><\/strong>Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas. J Inflamm Res. 2022 Sep 18;15:5413-5423.<\/li>\n\n\n\n
  5. Topkan E, Selek U, Haksoyler V, Kucuk A, Durankus NK, Sezen D, Bolukbasi Y, Pehlivan B. Postchemoradiotherapy Neutrophil-to-Lymphocyte Ratio Predicts Distant Metastasis and Survival Results in Locally Advanced Pancreatic Cancers. Int J Clin Pract. 2022 Jan 31;2022:7473649.<\/li>\n\n\n\n
  6. Yalcin K, Pehlivan B<\/u><\/strong>, Celen S, Bas EG, Kabakci C, Pashayev D, Daloglu H, Zhumatayev S, Uygun V, Karasu GT, Hazar V, Yesilipek A. Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL. J Pediatr Hematol Oncol2021 Mar 31.<\/li>\n\n\n\n
  7. Kucuk A, Topkan E, Selek U, Haksoyler V, Mertsoylu H, Besen AA, Pehlivan B<\/u><\/strong>. High Measures of Pre-Chemoradiotherapy Platelet-to-Albumin Ratio Indicates Poor Prognosis in Locally Advanced Pancreatic Cancer Patients. Ther Clin Risk Manag. 2022 Apr 14;18:421-428.<\/li>\n\n\n\n
  8. Topkan E, Selek U, K\u00fc\u00e7\u00fck A, Haks\u00f6yler V, \u00d6zdemir Y, Sezen D, Mertsoylu H, Besen AA, B\u00f6l\u00fckba\u015f\u0131 Y, \u00d6zy\u0131lkan O, Pehlivan B<\/strong>. Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB\/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis. J Oncol 2021 Jan 23;2021.<\/li>\n\n\n\n
  9. K\u00fc\u00e7\u00fck A, Ozkan EE, \u00d6ztep SE, Mertsoyle H, Pehlivan B<\/u><\/strong>, Selek U, Topkan E. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. J Oncol 2020 Dec 16.<\/li>\n\n\n\n
  10. Topkan E, Besen AA, Mertsoylu H, Kucuk A, Pehlivan B<\/u><\/strong>, Selek U. Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide.<\/a> Int J Inflam. 2020 Jun 8;2020.<\/li>\n\n\n\n
  11. Topkan E, Mertsoylu H, Kucuk A, Besen AA, Sezer A, Sezen D, Bolukbasi Y, Selek U, Pehlivan B<\/u>. <\/strong>Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy.<\/a> Gastroenterol Res Pract. 2020 Jul 30;2020.<\/li>\n\n\n\n
  12. Topkan E, Ozdemir Y, Guler OC, Kucuk A, Besen AA, Mertsoylu H, Sezen D, Akdemir EY, Sezer A, Bolukbasi Y, Pehlivan B<\/u><\/strong>, Selek U.  Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB\/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy: A Propensity Score Matching Study.<\/a> J Oncol. 2020 Sep 4;2020.<\/li>\n\n\n\n
  13. Topkan E, Kucuk A, Ozdemir Y, Mertsoylu H, Besen AA, Sezen D, Bolukbasi Y, Pehlivan B<\/u><\/strong>, Selek U. Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol.<\/a> J Immunol Res. 2020 Nov 14;2020.<\/li>\n\n\n\n
  14. Kucuk A, Ozkan EE, Eskici Oztep S, Mertsoylu H, Pehlivan B<\/u><\/strong>, Selek U, Topkan E. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. J Oncol2020 Dec 16;2020.<\/li>\n\n\n\n
  15. Topkan E, Besen AA, Ozdemir Y, Kucuk A, Mertsoylu H, Pehlivan B<\/u><\/strong> and Selek U. Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Post-neurosurgical Radiotherapy plus Concurrent and Adjuvant Temozolomide. Mediators Inflamm. 2020 23;2020.<\/li>\n\n\n\n
  16. Kucuk A, Topkan E, \u0130kiz ED, Duranku\u015f N, Senyurek S, Aydemir EY, Sezen D, Bolukba\u015f\u0131 Y, Selek U, Pehlivan B<\/u><\/strong>. Combination of stereotactic radiosurgery with immunotherapy: is it a new treatemnt option for brain metastases? Int Res J Oncol, 2020.<\/li>\n\n\n\n
  17. Topkan E, K\u00fc\u00e7\u00fck A, \u015eeny\u00fcrek S, Sezen D, Duranku\u015f NK, Aydemir EY, \u0130kiz ED, B\u00f6l\u00fckba\u015f\u0131 Y, Pehlivan B<\/u><\/strong> ve Selek U. Preoperative radiosurgery in management of brain metastases. J Cancer Tumor Int, 10(1):1-11, 2020.<\/li>\n\n\n\n
  18. Topkan E, K\u00fc\u00e7\u00fck A, Sezen D, Seny\u00fcrek S, Aydemir EY, Duranku\u015f N, \u0130kiz ED, Bol\u00fckba\u015f\u0131 Y, Pehlivan B<\/u><\/strong> ve Selek U. Common prognostic scoring system for patients presenting with brain metastases. Clin Oncol Res, 2020.<\/li>\n\n\n\n
  19. Pehlivan B<\/u><\/strong>, Topkan E, K\u00fc\u00e7\u00fck A, Okumu\u015f A, Sezen D, B\u00f6l\u00fckba\u015f\u0131 Y, Selek U. Stereotactic radiosurgery and targeted therapies for brain metastases from solid cancers. JAMMR,ISSN:2456-8899.<\/li>\n\n\n\n
  20. Topkan E, K\u00fc\u00e7\u00fck A, Duranku\u015f NK, \u015eeny\u00fcrek \u015e, Akdemir EY, Sezen D, \u0130kiz ED, B\u00f6l\u00fckba\u015f\u0131 Y, Pehlivan B<\/u><\/strong>, Selek U. Radiosurgical management of brainstem metastasis. Int Res J Oncol, 2020 3(1):37-46.<\/li>\n\n\n\n
  21. Sa\u011flam Y, B\u00f6l\u00fckba\u015f\u0131 Y, Atasoy A\u0130, Karak\u00f6se F, Alpan V, Selek U, K\u00fc\u00e7\u00fck A, Pehlivan B,<\/u><\/strong> Topkan E. Quality assurance in stereotactic radiosurgery and stereotactic body radiotherapy. Advances in Research 21 (7), 22-33.<\/li>\n\n\n\n
  22. Topkan E, K\u00fc\u00e7\u00fck A, \u015eeny\u00fcrek \u015e, Sezen D, Duranku\u015f NK, Akdemir EY, Sa\u011flam Y, B\u00f6l\u00fckba\u015f\u0131 Y, Pehlivan B<\/u><\/strong>, Selek U. Radiosurgery techniques for brain metastases. JCTI 2020; 10, 1-14.<\/li>\n\n\n\n
  23. B\u00f6l\u00fckba\u015f\u0131 Y, Selek U, Sezen D, Duranku\u015f NK, Akdemir EY, \u015eeny\u00fcrek \u015e, K\u00fc\u00e7\u00fck A, Pehlivan B<\/u><\/strong>, Topkan E. Tumor cavity stereotactic radiosurgery for resected brain metastases. JCTI 2020, 10(2):15-30.<\/li>\n\n\n\n
  24. Pehlivan B<\/u><\/strong>, Sengul K, Yesil A, Nalbant N, Ozturk O, Ozdemir Y, Topkan E. Dosimetric comparison of lung-sparing radiation therapy between volumetric arc therapy and helical tomotherapy for unresectable malignant pleural mesothelioma. BioMed Res Int, 2019.<\/li>\n\n\n\n
  25. Pehlivan B<\/u><\/strong>, Kucuk A, Mertsoylu H, Topkan E. Current management of brainstem gliomas. Int. J.Adv. Res. 7(9), 2019.<\/li>\n\n\n\n
  26. Topkan E, Pehlivan B<\/u><\/strong>. Radiation-induced abscopal effects on cardiovascular system. IndJMedResPharmSci, 6(9), 2019.<\/li>\n\n\n\n
  27. Golusinski P, Di Maio P, Pehlivan B<\/u><\/strong>, Colley S, Nankivell P, Kong A, Hartley A, Mehanna H. Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. Oral Oncol. 2019 Jan;88:145-152.<\/li>\n\n\n\n
  28. Topkan E, Selek U, Ozdemir Y, Besen AA, Guler OC, Yildirim BA, Mertsoylu H, Findikcio\u011flu A, Ozy\u0131lkan O, Pehlivan B. Risk factors for .fatal pulmonary hemorrahage following concurrent chemoradiotherapy in stage 3B\/C squamous-cell lung carcinoma patients. J Oncol 2018 Nov 1;2018.<\/li>\n\n\n\n
  29. Topkan E, Yildirim BA, Guler OC, Parlak C, Pehlivan B<\/u><\/strong>, Selek U. Safety and palliative efficacy of single-dose-8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):774-80.<\/li>\n\n\n\n
  30. Duman E, Cecen Y, S\u0131nd\u0131r B, Ozdemir B, Y\u0131ld\u0131r\u0131m M, Cecen S, Pehlivan B<\/u><\/strong>, Yavuz MN. Dosimetric evaluation of Adaptive Therapy in non-small lung cancer patients undergoing palliative thoracic Radiotherapy. Int J Hematol Oncol. 2015, 25:178-185.<\/li>\n\n\n\n
  31. Mirimanoff RO, Ozsahin M, Thariat J, Ozyar E, Schick, Pehlivan B<\/u><\/strong>, Krengli M, Pellanda AF, Vess H. Cai L, Scandolaro L, Belacemi Y, Villa S, Igdem S, Lutsyk M, Miller RC. History of rare cancer network and past research. Rare Tumors. 2014 Aug 6;6(3):5462.<\/li>\n\n\n\n
  32. Sar\u0131ca FB, Cekinmez M, Tufan K, Sen O, Onal HC, Mertsoylu H, Topkan E, Pehlivan B<\/u><\/strong>, Erdogan B, Altinors B. Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and efeectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma. Asian J Neurosurg. 2012 Oct;7(4):181-90.<\/li>\n\n\n\n
  33. Topkan E. Parlak C, Topuk S, Pehlivan B<\/u><\/strong>. Influence on oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. BMC Cancer 2012 Oct 31;12:502.<\/li>\n\n\n\n
  34. Pehlivan B<\/u><\/strong>, Ares C, Lomax T, Stadelmann O, Goitein G, Timmermann B, Schneider RA, Hug EB.: Temporal lobe toxicity analyasis after proton radiation therapy for skull base tumors. Int J Radiat Oncol Biol Phys 2012 Aug 1;83(5):1432-40.<\/li>\n\n\n\n
  35. Topkan E, Parlak C, Kotek A, Yuksel O, Cengiz M, Ozsahin M, Pehlivan B<\/u><\/strong>. Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens. Int J Radiat Oncol Biol Phys 2012 July 15;83(4):1264-71.<\/li>\n\n\n\n
  36. Pehlivan B<\/u>, <\/strong>Onal C, Yavuz M.: Retinoblastoma Tedavisinde Eksternal Radyoterapinin Rol\u00fc ve Radyoterapi Se\u00e7enekleri<\/a>. Int J. Hematol Oncol. 2012, 22(2):1-9.<\/li>\n\n\n\n
  37. Topkan E, Parlak C, Kotek A, Yapar AF, Pehlivan B<\/u><\/strong>. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol 2011 10,11:123.<\/li>\n\n\n\n
  38. Topkan E, Topuk S, Oymak E, Parlak C, Pehlivan B<\/u><\/strong>. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. Am J Clin Oncol 2012; 35(3):284-9.<\/li>\n\n\n\n
  39. Sar\u0131ca F, Tufan K, \u00c7ekinmez M, \u015een O, Onal HC, Mertsoylu H, Pehlivan B<\/u><\/strong>, Erdo\u011fan B, Alt\u0131nors MN. Effectiveness of temozolomide treatment used at thesame time with radiotherapyand adjuvant temozolomid: concomitant therapy of glioblastoma multiforme:         multivariate analysis and other prognostic factors. J Neurosurg Sci. 2010; 54(1): 7-19.<\/li>\n\n\n\n
  40. Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, Pehlivan B<\/u><\/strong>, Azria D, Roelandts M, Kaanders JH, Cengiz M, Krengli M, Matzinger O, Zouhair A.: Outcome and prognost\u0131c factors \u0131n olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):992-7.<\/li>\n\n\n\n
  41. Yavuz MN, Topkan E, Yavuz AA, Aydin M, Onal C, Reyhan M, Kotek A, Pehlivan B<\/u><\/strong>, Yapar AF.: FDG-PET\/CT Imaging-based taget volume delineation for preoperative conformal radiotherapy for rectal carcinoma. Int J Hematol Oncol 2010, 20(2):067-074.<\/li>\n\n\n\n
  42. Pehlivan B<\/u>, <\/strong>Topkan E, Onal C, Nursal GN, Y\u00fcksel O, Yavuz M, Yavuz A.: Comparison of CT and integrated PET-CT based radiation therapy planning in malign plevral mesothelioma patients. Radiat Oncol. 2009, 4:35.<\/li>\n\n\n\n
  43. Pehlivan B,<\/u><\/strong> Luthi F, Matzinger O, Betz M, Dragusanu D, Bulling S, Bron L, Pasche P, Seelentag W, Mirimanoff RO, Zouhair A, Ozsahin M.: Feasibility and efficacity of accelerated weekly concomitant boost postopeartive radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer. Ann Surg Oncol. 2009, 16:1337-1343.<\/li>\n\n\n\n
  44. Pehlivan B,<\/u> <\/strong>Pichenot C, Casting M, Auperin A, Arriagada R, Bourhis J.: Interfractional set-up errors evaluation by daily electronic portal imaging of IMRT in head and neck cancer patients. Acta Oncol. 2009, 48(3):440-5.<\/li>\n\n\n\n
  45. Pehlivan B,<\/u><\/strong> Zouhair A, Luthi F, Bron L, Pasche P, Dragusanu D, Azria D, Matzinger O, Mirimanoff RO, Ozsahin M.: Decrease in hemoglobin levels following surgery influences the outcome in head and neck cancer patients treated with accelerated postoperative radiotherapy. Ann Surg Oncol. 2009, 16:1331-1336.<\/li>\n\n\n\n
  46. Onal C, Arslan G, Topkan E, Pehlivan B<\/u><\/strong>, Yavuz M, Oymak E, Yavuz A.: Comparison of conventional and CT-based planning for intracavitary brachytherapy for cervical cancer: target volume coverage and organs at risk doses. J Exp Clin Cancer Res. 2009 Jul 1;28:95.<\/li>\n\n\n\n
  47. Onal C, Pehlivan B<\/u><\/strong>, Bal N, Topkan E, Kilinc F, Topuk S. : Sarcomatoid Carcinoma of the Urinary Bladder Treated with Adjuvant Radiotherapy: A Case Report. Clinical Medicine: Case Reports 2009:2 39-42.<\/li>\n\n\n\n
  48. Onal C, Yuksel O, Topkan E, Pehlivan B.<\/u> <\/strong>: Bilateral glomus tumor treated with PET-CT based conformal radiotherapy: case report. Cases Journal 2009, 2:8402.<\/li>\n\n\n\n
  49. Atahan IL, Y\u0131ld\u0131z F, Ozyar E, Pehlivan B<\/u><\/strong>, Gen\u00e7 M, K\u00f6se M, Tulunay G, Ayhan A, Yuce K, G\u00fcler N, Kucukali T.: Radiotherapy in the adjuvant setting of cervical carcinoma: treatment, results, and prognostic factors. Int J Gynecol Cancer 2007, 17 (4): 813-820.<\/li>\n\n\n\n
  50. Garcia R, Bourhis J, Pehlivan B<\/u><\/strong>, Pichenot C, Alfonsi M.: Intensity modulated radiotherapy for cancers of the upper aerodigestive tract. Cancer Radiother 2007, 11(6-7):353-7.<\/li>\n\n\n\n
  51. Pehlivan B<\/u><\/strong>, <\/strong>Topkan E, Yavuz A.: Protonterapy in clinical use. Ege T\u0131p Dergisi, 50(1):1-6, 2011<\/li>\n<\/ol>\n\n\n\n

    B. Proceedings, die auf internationalen wissenschaftlichen Tagungen pr\u00e4sentiert und im Proceedings Book ver\u00f6ffentlicht wurden:<\/strong><\/p>\n\n\n\n

    B1<\/strong>. Pehlivan B,<\/strong>Zouhair A, Luthi F, Bron l, Pasche P, Seelentag W, Mirimanoff RO, Ozsahin M.: Accelerated weekly concomitant boost postoperative radiation therapy combined to concomitant chemotherapy in patients with locally advanced head and neck cancer. Scientific Association of  Swiss Radiation Oncology (SASRO), Mart 2007, Aarau, \u0130svi\u00e7re.<\/p>\n\n\n\n

    B2. <\/strong>Pehlivan B<\/strong>, Ozsahin M, Bron L, Pasche P, HP Do, Luthi F,  Mirimanoff RO, Pica A.: High-dose rate brachytherapy in the treatment of recurrent head and neck cancer. Scientific Association of Swiss Radiation Oncology (SASRO), Mart 2007, Aarau, \u0130svi\u00e7re.<\/p>\n\n\n\n

    B3. <\/strong>Pehlivan B<\/strong>, Ares C, Stadelmann O, Lomax T, Hug EB.: Temporal lobe toxicity analysis following spot scanning proton radiation therapy for skull base tumors. Internatinal Translational Research Congress in Radiation Oncology, Mart 2009, Cenevre, \u0130svi\u00e7re.<\/p>\n\n\n\n

    B4.<\/strong> Ozsahin M, Olszyk O, Karakoyun-Celik O, Pehlivan B<\/strong>, Azria D, Roelandts M,  Kaanders JH, Cengiz M, Krengli M, Zouhair A.: Outcome and prognostic factors in olfactory neuroblastoma: a multicenter rare cancer network study. American Society of Therapeutic Radiation Oncology (ASTRO), Ekim 2005, Denver, ABD.<\/p>\n\n\n\n

    B5.<\/strong> Zouhair A, Dragusanu D, Matzinger O, Pehlivan B<\/strong>, Khanfir K, Ris HB, Stupp R, Moeckli RO, Ozsahin M.: Postoperative 3D conformal radiation therapy with dose-volume histogram assesment in non small-cell lung cancer. American Society of Therapeutic Radiation Oncology (ASTRO), Ekim 2007, Los Angeles, ABD.<\/p>\n\n\n\n

    B6.<\/strong> Dhermain F, Ducreux D, Bidault F, Parker F, Pehlivan B<\/strong>, Beaudre A, Haie-Meder C, Bourhis J.: Radiotherapy planning for WHO grade 2 and grade 3 supra-tentorial gliomas: first experience with 10 consecutive patients. The European Cancer Conference (ECCO) 13, Ekim 2005, Paris, Fransa.<\/p>\n\n\n\n

    B7.<\/strong> Atahan L, Y\u0131ld\u0131z F, Ozyar E, Pehlivan B<\/strong>, K\u00f6se F, Tulunay G, Ayhan A, Y\u00fcce K, G\u00fcler N, K\u00fc\u00e7\u00fckali T.: Radiotherapy in the adjuvant setting of cervical carcinoma: Treatments results and prognostic factors. European Society of Therapeutic Radiation Oncology (ESTRO) Annual Meeting, Ekim 2006, Leipzig, Almanya.<\/p>\n\n\n\n

    B8.<\/strong> Pehlivan B,<\/strong>Pichenot C, Casting M, Auperin A, Arriagada R, Bourhis J.: Verification of patient position by daily electronic portal imaging in head and neck cancer traeted with IMRT. European Society of Therapeutic Radiation Oncology (ESTRO) Annual Meeting, Ekim 2006, Leipzig, Almanya.<\/p>\n\n\n\n

    B9.<\/strong> Pehlivan B<\/strong>, Rutz HP, Goiten G, Haller K, Lomax A, Hug E, Timmermann B.: Case Report: Proton radiation therapy for secondary atypical lumbar meningioma arising 25 years after interdisciplinary treatment for advanced wilms tumor. European Society of Therapeutic Radiation Oncology (ESTRO) Annual Meeting, Eyl\u00fcl 2008, G\u00f6teborg, \u0130sve\u00e7.<\/p>\n\n\n\n

    B10. <\/strong>Pehlivan B<\/strong>, Kotek A, Akkaneren S, Topkan E. Outcome of profilactic cranial irradiation in 112 patients with recursive partitioning analysis group I locally advanced (Stage IIIB) non-small cell lung carcinoma. European Society of Therapeutic Radiation Oncology (ESTRO) Annual Meeting, Eyl\u00fcl 2010, Barselona, \u0130spanya.<\/p>\n\n\n\n

    B11. <\/strong>Pehlivan B<\/strong>, Yuksel O, Akkaneren \u015e, Topkan E.Pseudoprogression in patients with glioblastome multiforme following concurrent radiotherapy and temozolomide. European Society of Therapeutic Radiation Oncology (ESTRO) Annual Meeting, Eyl\u00fcl 2010, Barselona, \u0130spanya.<\/p>\n\n\n\n

    B12. <\/strong>Pehlivan B<\/strong>, Akkaneren \u015e, Kotek A, Topkan E. Survival outcome in unresectable locally advanced pancreatic carcinoma patients treated with coregistered PET-CT based radiation therapy planning without elective nodal irradiation. European Society of Therapeutic Radiation Oncology (ESTRO) Annual Meeting, Eyl\u00fcl 2010, Barselona, \u0130spanya.<\/p>\n\n\n\n

    B13. <\/strong>Pehlivan B<\/strong>, <\/strong>Oymak E, Kotek A, Akkaneren S, Topkan E. Oral glutamine supplementation for amelioration of acute radiation induced esophagitis has no negative impact on survival outcome in locally advanced non-small cell lung cancer treated with thoracic irradiation. European Society of Therapeutic Radiation Oncology (ESTRO) Annual Meeting, Eyl\u00fcl 2010, Barselona, \u0130spanya.<\/p>\n\n\n\n

    B14. <\/strong>Pehlivan B<\/strong>, Kotek A, Akkaneren S, Topkan E: Comparison of CT and PET\/CT based radiotherapy planning in hepatic metastases from colorectal and breast primaries. 5th <\/sup>International Asian Pacific Organization for Cancer Prevention Conference, Nisan 2010, \u0130stanbul<\/p>\n\n\n\n

    B15<\/strong>. Parlak C, Pehlivan B<\/strong>, Oymak E, Topuk S, Topkan E. Prognostic Importance of Gross Tumor Volume Defined by Utilizing 18-FDG-PET\/CT in Stage IIIB Non-small Cell Lung Carcinoma Treated with Definitive Chemoradiotherapy. European Multidisciplinary Conference on Thoracic Oncology 2010 Abstract Book. Lung Cancer 71 suppl. 2: 2011<\/p>\n\n\n\n

    B16.<\/strong> Topkan E, Yuksel E, Kotek A, Parlak C, Pehlivan B<\/strong>. Oral glutamine supplementation has no negative impact on survival in locally advanced non-small cell lung cancer treated with coccurrent chemotherapy. European Multidisciplinary Conference on Thoracic Oncology 2010 Abstract Book. Lung Cancer 71 suppl. 2: 2011<\/p>\n\n\n\n

    B17. <\/strong>Pehlivan B<\/strong>,<\/strong> Kotek A, Yuksel O, Topkan E.<\/strong> Impact of Chemotehrapy Sequence on Brain Relaps Rates in Patients with Stage IIIB Non-small Cell Lung Carcinoma Treated with Concurrent Chemoradiotherapy Plus Prophylactic Crainial Irradiation. European Multidisciplinary Conference on Thoracic Oncology 2010 Abstract Book. Lung Cancer 71 suppl. 2: 2011<\/p>\n\n\n\n

    B18. <\/strong>Topkan E, Parlak C, Guler OC, Pehlivan B<\/strong>, Selek U. Impact Of Pretreatment Leukocytosis On Prognosis In Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Concurrent Chemoradiotherapy. 15th<\/sup> World Conference on Lung Cancer, Sydney, Australia. J Thorac Oncol 8 (Supplement 2)<\/p>\n\n\n\n

    B19.<\/strong> Topkan E, Parlak C, Pehlivan B<\/strong>, Ozyilkan O, Selek U. Efficacy Of Single Dose 8-Gy Palliative Chest Irradiation In Pain Palliation Of Patients With Locoregionally Recurrent Stage IV Non-small Cell Lung Cancer. 15th<\/sup> World Conference on Lung Cancer, Sydney, Australia. J Thorac Oncol 8 (Supplement 2)<\/p>\n\n\n\n

    B.20.<\/strong> Topkan E, Parlak C, Guler OC, Pehlivan B<\/strong>, Ozyilkan O, Selek U. Impact Of Change In Hemoglobin Levels During Treatment On Prognosis In Non-anemic Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Concurrent Chemoradiotherapy. 15th<\/sup> World Conference on Lung Cancer, Sydney, Australia. J Thorac Oncol 8 (Supplement 2):<\/p>\n\n\n\n

    B21.<\/strong> Topkan E, Parlak C, Pehlivan B<\/strong>, Selek U, Ozyilkan O. Prognosis Of Stage III Non-Small Cell Lung Cancer Patients Initially Presenting With Superior Vena Cava Syndrome Treated With Partially Accelerated Definitive Concurrent Chemoradiotherapy. 15th<\/sup> World Conference on Lung Cancer, Sydney, Australia. J Thorac Oncol 8 (Supplement 2): s1149: 2013.<\/p>\n\n\n\n

    B22.<\/strong> Topkan E, Parlak C, <\/strong>Pehlivan B<\/strong>, Ozyilkan O, Selek U. Long Treatment Duration Is Associated With Poor Prognosis In Patients Receiving Concurrent Chemoradiotherapy With The Diagnosis Of Stage IIIB Non-Small Cell Lung Cancer. 15th<\/sup> World Conference on Lung Cancer, Sydney, Australia. J Thorac Oncol 8 (Supplement 2)<\/p>\n\n\n\n

    B23. <\/strong>Ye\u015fil A, Topkan E, \u00d6zcan D, Ta\u015f\u00e7\u0131 N, Yilmaz F, Meral \u00d6, Pehlivan B<\/strong>. Hippocampi and Scalp Sparing Whole Brain Radiotherapy and Simultaneous Integrated Boost in Patients Presenting with Multiple Brain Metastases. Accuray User Meeting, Nisan 2016, San Francisco, USA<\/p>\n\n\n\n

    B24.<\/strong> Ye\u015fil A, \u00d6zcan D, Ta\u015f\u00e7\u0131 N, Bayaz\u0131t B,Pehlivan B<\/strong>. <\/strong>Comparison of Adjuvant Radiotherapy with Tomo-Helical and Tomo-Direct Treatment Techniques in Breast Cancer. Accuray User Meeting, Nisan 2016, San Francisco, USA<\/p>\n\n\n\n

    B25.<\/strong> Ta\u015f\u00e7\u0131 N, Ye\u015fil A, Y\u0131lmaz \u0130, Y\u0131lmaz F, Meral \u00d6, \u00d6zcan D, Topkan E, Pehlivan B<\/strong>. The Investigation of Treatment Accuracy for Breast Cancer Radiotherapy Based on Daily Imaging. Accuray User Meeting, Nisan 2016, San Francisco, USA<\/p>\n\n\n\n

    B26.<\/strong> Ta\u015f\u00e7\u0131 N, Ye\u015fil A, Y\u0131lmaz I, \u00c7il A, Meral \u00d6, \u00d6zcan D, Pehlivan B<\/strong>. Adaptive Managemet Plans and Investigation of Accuracy of Lung Radiosurgery. Accuray User Meeting, Nisan 2016, San Francisco, USA<\/p>\n\n\n\n

    C. Artikel, die in nationalen Peer-Review-Zeitschriften ver\u00f6ffentlicht wurden:<\/strong><\/p>\n\n\n\n

    C1.<\/strong> Pehlivan B<\/strong>, Topkan E, Yavuz A.: Protonterapy in clinical use. Ege T\u0131p Dergisi, 50(1):1-6, 2011<\/p>\n\n\n\n

    D.\u00a0Bei nationalen wissenschaftlichen Tagungen pr\u00e4sentierte und im Proceedings Book ver\u00f6ffentlichte Papiere:<\/strong><\/p>\n\n\n\n

    D1. <\/strong>Pehlivan B<\/strong>, <\/strong>Zorlu F, Y\u0131ld\u0131z F, G\u00fcrkaynak M, Akyol F, Kars A, Atahan IL.: Preoperatif radyoterapi alan rektum kanserli hastalarda sonu\u00e7lar\u0131m\u0131z. Ulusal Kanser Kongresi, Nisan 2004, Antalya.<\/p>\n\n\n\n

    D2. <\/strong>Pehlivan B<\/strong>, <\/strong>Zorlu F, Cengiz M, Akyol F, G\u00fcrkaynak M, Altunda\u011f K, Tekuzman G, Atahan LI.: Opere mide kanserli hastalarda adjuvan radyoterapi sonu\u00e7lar\u0131 ve prognostik fakt\u00f6r analizi. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2004, Antalya.<\/p>\n\n\n\n

    D3.<\/strong> Dhermain F, Pehlivan B<\/strong>, Ducreux D, Beaudre A, Bidault F, Parker F, Haie-Meder C, Lefkopoulos D, Bourhis J.: Grad 2 ve Grad 3 oligodendriogliomlu hastalar\u0131n radyoterapi planlamas\u0131nda fonksiyonel magnetik resonans\u0131n yeri:ilk 10 hastan\u0131n sonu\u00e7lar\u0131. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2006, Antalya.<\/p>\n\n\n\n

    D4.<\/strong> Yavuz MN, Pehlivan B<\/strong>, Ayd\u0131n M, Topkan E, \u00d6nal C, Reyhan M, K\u00f6tek A, Yapar AF, Yavuz AA.: Rektum kanserinin preoperatif radyoterapisinde BT ile PET-BT bazl\u0131 3-boyutlu konformal radyoterapi planlar\u0131n\u0131n kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131. XVIII. Ulusal Kanser Kongresi, Nisan 2009, Antalya.<\/p>\n\n\n\n

    D5<\/strong>. Pehlivan B,<\/strong>Yavuz M, Topuk S, Topkan E, Yavuz A.: Servikal vertebra agresif osteoblastomlu hastada 18- FDG-PET-BT bazl\u0131 k\u00fcratif radyoterapi: olgu sunumu. Ulusal Kanser Kongresi, Nisan 2009, Antalya.<\/p>\n\n\n\n

    D6. <\/strong>S\u00f6nmez A,Pehlivan B<\/strong>, <\/strong>Arslan G, Yavuz A, Topkan E, S\u00f6nmez S, Yavuz M.: T\u00fcm v\u00fccut \u0131\u015f\u0131nlamas\u0131nda multi leaf kolimat\u00f6r ile ikincil alt alan tekni\u011fi. Ulusal Kanser Kongresi, Nisan 2009, Antalya.<\/p>\n\n\n\n

    D7.<\/strong> \u00d6nal C, Oymak E, Arslan G, Pehlivan B<\/strong>, Topkan E, Yavuz MN, Yavuz AA.: \u0130ntrakaviter brakiterapi uygulanan serviks kanserli hastalarda konvansiyonel plan ile 3 boyutlu plan\u0131n kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131. XVIII. Ulusal Kanser Kongresi, Nisan 2009, Antalya.<\/p>\n\n\n\n

    D8.<\/strong> \u00d6nal C, Kayasel\u00e7uk F, Erdem R, Oymak E, Pehlivan B<\/strong>, Topkan E, Yavuz M, Bacanl\u0131 D, Yavuz A.: Radyasyon enteritinin \u00f6nlenmesinde melatonin ve oktreotidin etkinliklerinin kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131. XVIII. Ulusal Kanser Kongresi, Nisan 2009, Antalya.<\/p>\n\n\n\n

    D9. <\/strong>Pehlivan B<\/strong>, Ares C, Stadelmann O, Lomax A, Goitein G, Timmermann B, Schneider R, Hug EB. Protonterapi uygulanan kafa taban\u0131 kordoma ve kondrosarkomalar\u0131nda temporal lob toksisitesi analizi. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2010, Girne.<\/p>\n\n\n\n

    D10. <\/strong>Pehlivan B<\/strong>,<\/strong> K\u00f6tek A, Akkaneren \u015e, Topkan E. PET-BT bazl\u0131 radyoterapi planlamas\u0131 sonras\u0131 elektif nodal \u0131\u015f\u0131nlama yap\u0131lmaks\u0131z\u0131n tedavi edilen lokal ileri evre pankreas kanserinde sa\u011fkal\u0131m sonu\u00e7lar\u0131. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2010, Girne.<\/p>\n\n\n\n

    D11. <\/strong>Pehlivan B<\/strong>.<\/strong> K\u00f6tek A, Akkaneren \u015e, Topkan E. Lokal ileri evre k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri tan\u0131s\u0131 nedeniyle ard\u0131\u015f\u0131k veya e\u015fzamanl\u0131 kemoradyoterapi uygulanan hastalarda profilaktik kranyal \u0131\u015f\u0131nlama. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2010, Girne.<\/p>\n\n\n\n

    D12. <\/strong>Pehlivan B<\/strong>, Yuksel O, Akkaneren \u015e, Topkan E. Radyoterapi ve e\u015f zamanl\u0131 temozolomid ile tedavi edilen glioblastoma multiforme hastalar\u0131nda ps\u00f6doprogresyon. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2010, Girne.<\/p>\n\n\n\n

    D13. <\/strong>Pehlivan B<\/strong>. <\/strong>K\u00f6tek A, Akkaneren \u015e, Topkan E. Karaci\u011fer metastazlar\u0131 tan\u0131l\u0131 hastalarda BT ve PET\/BT f\u00fczyonu bazl\u0131 radyoterapi planlar\u0131n\u0131n kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2010, Girne.<\/p>\n\n\n\n

    D14. <\/strong>Pehlivan B<\/strong>, K\u00f6tek A, Akkaneren \u015e, Topkan E. FDG-PET\/BT bazl\u0131 \u00fc\u00e7 boyutlu konformal radyoterapi plan\u0131 ile tedavi edilen karaci\u011fer metastazlar\u0131nda lokal kontrol ve sa\u011fkal\u0131m sonu\u00e7lar\u0131. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2010, Girne.<\/p>\n\n\n\n

    D15. <\/strong>Pehlivan B<\/strong>, K\u00f6tek A, Akkaneren \u015e, Topkan E. Profilaktik oral glutamin kullan\u0131m\u0131n\u0131n e\u015f zamanl\u0131 pelvik radyokemoterapiye ba\u011fl\u0131 akut diareyi \u00f6nlemedeki etkisinin retrospektif olarak de\u011ferlendirilmesi. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2010, Girne.<\/p>\n\n\n\n

    D16. <\/strong>Pehlivan B<\/strong>, Oymak E, Akkaneren \u015e, K\u00f6tek A, Topkan E. Profilaktik oral glutamine kullan\u0131m\u0131n\u0131n torasik radyoterapi ile tedavi edilen k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanserlerinde radyoterapiye sa\u011fkal\u0131m \u00fczerine etkisi. Ulusal Radyasyon Onkolojisi Kongresi Nisan 2010, Girne.<\/p>\n\n\n\n

    D17.<\/strong> Pehlivan B<\/strong>, Yavuz MN, Bal N, Topkan C, \u00d6nal C, Yavuz AA. Radyoterapinin testiste olu\u015fturdu\u011fu hasar\u0131n \u00f6nlenmesinde amifostin, melatonin ve 5-androstenediol\u2019un radyoprotektif etkinliklerinin kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2010, Girne.<\/p>\n\n\n\n

    D18.<\/strong> K\u00f6tek A, Pehlivan B<\/strong>, Ac\u0131bucu \u0130, D\u00f6lek Y, Yavuz AA, Yavuz E, Topkan E. Meme Koruyucu cerrahi veya modifiye radikal mastektomi sonras\u0131 4 farkl\u0131 teknikle 3 boyutlu konformal radyoterapi uygulanan hastalardaki kar\u015f\u0131 meme dozu. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2010, Girne.<\/p>\n\n\n\n

    D19.<\/strong> Eren \u015e, Y\u00fcksel \u00d6, K\u00f6tek A, Oymak E, Topuk S, Pehlivan B<\/strong>, \u00d6nal C, Topkan E. \u201cServikal kanser tan\u0131l\u0131 ve brakiterapi uygulanamayan hastalarda \u00fc\u00e7 boyutlu konformal boost tedavisi sonu\u00e7lar\u0131. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2010, Girne.<\/p>\n\n\n\n

    D20. <\/strong>\u015eeng\u00fcl K, Toksoy T, \u00d6zturk O, \u00d6zt\u00fcrk H, Parlak C, Topkan E, Pehlivan B<\/strong>: Mali\u011fn Mezotelyoma Tedavisinde Helikal Tomoterapi ve Rapid Ark Tedavi Tekniklerinin Dozimetrik Olarak Kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131. 11. Ulusal Radyasyon Onkolojisi Kongresi,  Nisan 2014, Antalya.<\/p>\n\n\n\n

    D21.<\/strong> \u015eeng\u00fcl K, Toksoy T, \u00d6zturk O, Pehlivan B. <\/strong>Ba\u015f Boyun Kanserli Hastalarda 3 Farkl\u0131 Radyoterapi Tekni\u011finin Kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131. 11. Ulusal Radyasyon Onkolojisi Kongresi,  Nisan 2014, Antalya.<\/p>\n\n\n\n

    D22.<\/strong> Pehlivan B<\/strong>, Herrera F, Bouchaab H, Vallet V, Pasche P, Simon C, Bourhis J, \u00d6z\u015fahin M. N\u00fcks Ba\u015f Boyun Kanserli Hastalarda Postoperaif HDR Brakiterapi Sonu\u00e7lar\u0131. 11. Ulusal Radyasyon Onkolojisi Kongresi,  Nisan 2014, Antalya.<\/p>\n\n\n\n

    D23.<\/strong> \u00d6zturk O, \u015eeng\u00fcl K, Y\u0131lmaz G, Ozsahin M, Pehlivan B<\/strong>. Prostat Kanseri Tedavisinde Vol\u00fcmetrik Ayarl\u0131 Ark Tedavisi ve Yo\u011funluk Ayarl\u0131 Radyoterapinin Kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131. 11. Ulusal Radyasyon Onkolojisi Kongresi,  Nisan 2014, Antalya.<\/p>\n\n\n\n

    D24.<\/strong> Ye\u015fil A, Ta\u015f\u00e7\u0131 N, \u00d6zcan D, Bayaz\u0131t B, \u00c7il A, Pehlivan B.<\/strong> Total V\u00fccut I\u015f\u0131nlamalar\u0131nda Tomo-Helikal ve Tomo-Direk Tedavi Tekniklerinin Kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2016, Antalya<\/p>\n\n\n\n

    D25.<\/strong> \u00d6zcan D, Ye\u015fil A, Ta\u015f\u00e7\u0131 N, Y\u0131lmaz F, Meral \u00d6, Pehlivan B<\/strong>, Topkan E. \u201cSimultaneous Integrated Boost\u201d (SIB) Tekni\u011fiyle Skalp ve Hipokamp\u00fcs Koruyucu T\u00fcm Beyin I\u015f\u0131nlamas\u0131. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2016, Antalya<\/p>\n\n\n\n

    D26.<\/strong> Ta\u015f\u00e7\u0131 N, Ye\u015fil A, Y\u0131lmaz \u0130, Meral \u00d6, \u00d6zcan D, Pehlivan B.<\/strong> Akci\u011fer SBRT Planlar\u0131n\u0131n, Tedavi \u00d6ncesi ve Sonras\u0131 Al\u0131nan G\u00f6r\u00fcnt\u00fclerle Elde Edilen Adaptif Planlar ile Kar\u015f\u0131la\u015ft\u0131r\u0131larak Tedavi Do\u011frulu\u011funun Ara\u015ft\u0131r\u0131lmas\u0131. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2016, Antalya<\/p>\n\n\n\n

    D27.<\/strong> Ta\u015f\u00e7\u0131 N, Y\u0131lmaz \u0130, Ye\u015fil A,  Y\u0131lmaz F, Meral \u00d6, \u00d6zcan D, Pehlivan B.<\/strong> Meme Kanserli Hastalar\u0131n Radyoterapisinde Tedavi Do\u011frulu\u011funun Her Tedavi \u00d6ncesi Al\u0131nan MVCT G\u00f6r\u00fcnt\u00fcleriyle Olu\u015fturulan Adaptif Planlar Yard\u0131m\u0131yla Ara\u015ft\u0131r\u0131lmas\u0131. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2016, Antalya<\/p>\n\n\n\n

    D28.<\/strong> Ye\u015fil A, Ta\u015f\u00e7\u0131 N, Y\u0131lmaz F, \u00d6zcan D, Pehlivan B.<\/strong> Farkl\u0131 \u00c7aptaki Hedef Vol\u00fcmlere Yap\u0131lan Planlar ile Tomoterapinin Radyocerrahideki Etkinli\u011finin Ara\u015ft\u0131r\u0131lmas\u0131. Ulusal Radyasyon Onkolojisi Kongresi, Nisan 2016, Antalya<\/p>\n","protected":false},"excerpt":{"rendered":"

    Die BP-Klinik ist ein Ort, der nach dem Motto „personalisierte Gesundheit, personalisierte Onkologie“ mit \u00c4rzten und Spezialisten aus den verschiedensten Fachrichtungen arbeitet, was in dieser Form im Land beispiellos ist. Anders als das konventionelle Gesundheitssystem, welches darauf ausgerichtet ist, Erkrankungen zu behandeln, hilft es den Menschen, gar nicht erst krank zu werden. Prof. Dr. Berrin …<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-2936","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/bpklinik.com\/de\/wp-json\/wp\/v2\/pages\/2936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bpklinik.com\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bpklinik.com\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bpklinik.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bpklinik.com\/de\/wp-json\/wp\/v2\/comments?post=2936"}],"version-history":[{"count":3,"href":"https:\/\/bpklinik.com\/de\/wp-json\/wp\/v2\/pages\/2936\/revisions"}],"predecessor-version":[{"id":2976,"href":"https:\/\/bpklinik.com\/de\/wp-json\/wp\/v2\/pages\/2936\/revisions\/2976"}],"wp:attachment":[{"href":"https:\/\/bpklinik.com\/de\/wp-json\/wp\/v2\/media?parent=2936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}